Clarivate

DECEMBER 19, 2022

Either way, competition over employed providers among Medicare Advantage plans has only begun to heat up and UnitedHealth remains the plan to beat. Clarivate Associate Healthcare Research & Data Analysts Anubhav Sharma and Prashanth Jain contributed to this report. Medicare provider competition appeared first on Clarivate.

Competition 52

Competition Retail Insurance Marketing 52

Impetus Digital

MARCH 15, 2024

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). There are currently more than 2,000 oncology products under development.

Recruitment 78

Recruitment Healthcare Provider Patients Healthcare 78

MedCity News

JUNE 16, 2023

Numerous clinical, regulatory and financial factors are behind this digital shift in pharma. UCHealth providers are also notified of these potential changes and can intervene directly if warranted, driving the next level of tech-enabled personalized healthcare.

Pharma 106

Pharma Food and Drug Administration Recruitment Pharmacology 106

Pharmaceutical Technology

JUNE 15, 2023

AI in pharma R&D is one of the latest innovations helping teams apply existing knowledge to new problems. Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. Here are a few ways AI is used in pharma today.

Pharma 52

Pharma Management Networking Manufacturing 52

Clarivate

APRIL 24, 2023

healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. CVS’ bid for Oak Street is in keeping with nearly two decades of evolution toward becoming an integrated payer and provider.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarivate

JULY 31, 2023

Following the acquisition of Dialog Solutions as part of the ProQuest M&A in December 2021, Dialog Solutions products and services will be folded into the Clarivate portfolio of offerings for Life Sciences & Healthcare. To learn more about the Dialog platform, visit: here.

Healthcare 52

Healthcare Healthcare Safety Competition 52

Clarivate

JANUARY 23, 2024

To learn more about how Clarivate and CMR International help pharmas future-proof their portfolios, please visit us here. The post Pharma R&D productivity dips, but efficiency gains give hope appeared first on Clarivate. Jasmin Mehta is a Senior Manager within the Life Science Professional Services team at Clarivate.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., This is supported by epidemiology data from Evaluate Pharma. Europe, and parts of Asia.

Marketing 59

Marketing Biopharma Government Pharma 59

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience.

Education 59

Education Physicians Healthcare Healthcare 59

MedCity News

JANUARY 11, 2024

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

Competition 105

Competition Sales Marketing Biopharma 105

European Pharmaceutical Review

DECEMBER 19, 2022

She has experience on issues arising during the lifecycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, competition and market access issues. Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. References/Endnotes. Lausuntopalvelu.fi.

Medicine 52

Medicine Biopharma Safety Food 52

Clarivate

OCTOBER 25, 2021

OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery Intelligence and Cortellis Competitive Intelligence. As a next step in this journey, Bioinfogate will be fully integrated into the Clarivate product portfolio and renamed.

Safety 110

Safety Biopharma Competition Management 110

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). However, the ultimate impact of this program should have far-reaching effects for pharmaceutical companies and the broader healthcare system that bear monitoring as the IRA’s multi-year implementation schedule unfolds.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Clarivate

MAY 8, 2024

Doubling down on strategic therapeutic areas Pharma once again finds itself having to narrow its sights on partnerships that deliver the next blockbuster and enable differentiation from the competition—all while navigating increasing regulatory scrutiny and shifting patient and payer expectations.

Pharma 59

Pharma Biopharma Prospecting Competition 59

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Innovation Is Expanding, But Healthcare Systems Are Slow to Adapt. On average, they returned 11% less global revenue than previous years’ launches. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Clarivate

SEPTEMBER 26, 2023

In therapeutic areas where there is competition for trial participants (e.g. If trial sponsors can access this data in a trusted and layered way, RWD will save dollars and lives, a win-win for all stakeholders in the healthcare ecosystem. oncology), trial productivity is essential.

Food and Drug Administration 59

Food and Drug Administration Electronics Patients Healthcare 59

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent. References. [1]

Marketing 52

Marketing Safety Patients Competition 52

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

Clarivate

MAY 24, 2023

In recent years, FDA has increasingly shown an openness to surrogate endpoints as the basis for approval of a therapy,” said Bethany Kiernan, Director of Healthcare Research Analytics for Infectious, Niche and Rare Diseases at Clarivate.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Clarivate

DECEMBER 1, 2021

As part of our Drugs to Watch series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate experts have selected their top picks from the AHA21 Scientific Sessions. In the following article, we present our analysis of five featured abstracts and our key takeaways for healthcare executives.

Safety 52

Safety Patients Management Marketing 52

Pharmaceutical Technology

MARCH 21, 2023

In this month’s edition, which covers events from late January to early March, manufacturing contract-related data from GlobalData’s PharmSource reports and news from GlobalData’s Pharma Intelligence Center have been collated to identify stakeholders at the center of new developments.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

JANUARY 25, 2023

In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. In such times, experts expect partnerships between biotechs and big pharma, like the Anima Biotech/AbbVie deal announced earlier this month , to become even more popular.

Marketing 69

Marketing Biopharma Pharma Competition 69

Pharmaceutical Technology

JANUARY 15, 2023

In order to get a therapy to the market, pharma companies often outsource the drug manufacturing to specialist contract manufacturing organizations (CMOs). While Catalent Inc and PCI Pharma Services are in charge of the solid dose and packaging of Lupkynis, Lonza is manufacturing the small molecule API.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52

World of DTC Marketing

JUNE 7, 2021

The true risk to pharma in response to unacceptable drug pricing may come from growing bipartisan support to increase industry antitrust scrutiny and penalties. Eight US antitrust bills targeting the pharmaceutical industry have been recently introduced, addressing a gamut of alleged anti-competitive activity. AARP Drug Pricing.

Pharma 187

Pharma Retail Prescription Competition 187